A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
← catalyst calendarNCT07784725 · readout in 716 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
2,500estimated
Sites
212
Countries
Argentina, Australia, Brazil +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-19 | actual | When the study began enrolling |
| Primary completion | 2028-08-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-21 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity or Overweight
Interventions
- Drug: AZD6234
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change in body weight from baseline at 68 weeks of treatment
measured 68 weeks
Related
AZN · their whole pipeline · Obesity readouts · Congress trades in AZN
AZN's other studiesmost recently updated first
- Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Phase 4 · Active, not recruiting
- Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) Phase 3 · Recruiting
- Real-World Treatment Study of Koselugo (Selumetinib) — · Recruiting
- Fasenra Pediatric Japan Post-Marketing Study(PMS) — · Active, not recruiting
- AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database — · Recruiting
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed